Key facts
- It has raised $693.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($273.0M) in Sep 2023.
- Notable investors include Alumni Ventures, Fidelity Management & Research Company, Realm Capital Ventures, Mirae Asset Capital, ARCH Venture Partners — 23 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for Generate:Biomedicines
Funding rounds
2 roundsAbout Generate:Biomedicines
Developer of a generative biology platform designed to invent new drugs across protein modalities and therapeutics. The company's tool leverages machine learning to understand the genetic code underlying the function of proteins to generate antibodies, peptides, enzymes, and cell and gene therapies to meet any therapeutic need, enabling researchers to bring new medicines to patients.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Somerville, MA, United States
- Founded
- 2018
- Employees
- 325
- Website
- generatebiomedicines.com/
- Ownership
- Privately Held (backing)
Generate:Biomedicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Generate:Biomedicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Generate:Biomedicines in its N-PORT filings yet. We sweep new filings monthly.